Emiel J. Rutgers

The Netherlands Cancer Institute — Netherlands

Biochemistry, Genetics and Molecular Biology · Life Sciences

97h-index54.4kcitations771works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(467), Breast Lesions and Carcinomas(204), Breast Implant and Reconstruction(95), BRCA gene mutations in cancer(92), Cancer Genomics and Diagnostics(86)

Publications765 total

The Value of Ultrasound in Patients with T1–T2 Breast Cancer with No Palpable Lymph Nodes Enrolled in the EORTC 10981–22023 AMAROS Trial
Annals of Surgical Oncology·2025· 1 cited
Prognostication and treatment predictions for estrogen receptor positive early-stage breast cancer: incorporating the 70-gene signature into the PREDICT prognostication model
The Breast·2025Open Access
Abstract P1-05-26: MammaPrint Genomic Signature, Molecular Subtype Characteristics and Outcomes of HER2-Low Early Breast Cancer (EORTC10041 / BIG 03-04 MINDACT Trial)
Clinical Cancer Research·2025
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
UNC Libraries·2025· 17 citedOpen Access
Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial
European Journal of Cancer·2025· 8 cited
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
npj Breast Cancer·2024· 2 citedOpen Access
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial
iScience·2024· 1 citedOpen Access
Abstract GS02-05: Overview of Axillary Treatment in Early Breast Cancer: patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomised trials
Cancer Research·2024· 4 cited
Abstract PO1-14-11: Different molecular processes are associated with recurrence in the clinical high- genomic low risk (cH/gL) and clinical low- genomic high risk (cL/gH) groups of the MINDACT clinical trial
Cancer Research·2024
Early detection of breast cancer in high-risk women based on longitudinal changes in serum-based proteins: the TESTBREAST study, an update
European Journal of Surgical Oncology·2024
Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature
Journal of Clinical Oncology·2024· 6 cited
Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials
The Lancet·2023· 135 citedOpen Access
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
Annals of Oncology·2023· 192 citedOpen Access
Obesity-associated changes in molecular biology of primary breast cancer
Nature Communications·2023· 48 citedOpen Access
Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: A survey within the MINDACT cohort
The Breast·2023· 1 citedOpen Access
161P DESCARTES trial: De-ESCAlating RadioTherapy in patients with pathologic complete response to neoadjuvant systemic therapy
ESMO Open·2023Open Access
Supplementary Table from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
2023Open Access
Supplementary Table from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
2023Open Access
Supplementary Table from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
2023Open Access
Data from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
2023Open Access
page 1 of 39Next →

Frequent Co-authors

Martine Piccart(16), Fátima Cardoso(12), Jan Bogaerts(12), Michael Gnant(11), Giuseppe Viale(10), Jonas Bergh(9), Philip Poortmans(9), Annuska M. Glas(8), Beat Thürlimann(8), Laura J. van’t Veer(8), Marc J. van de Vijver(7), Johannes L. Peterse(7), Eric P. Winer(7), Harold J. Burstein(7), Giuseppe Curigliano(7), Sibylle Loibl(7), Cornelis J.�H. van de Velde(7), Meredith M. Regan(7), Laura van ‘t Veer(6), Richard D. Gelber(6)